Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
3.930
+0.040 (1.03%)
At close: Aug 24, 2026, 4:00 PM EDT
4.067
+0.137 (3.48%)
After-hours: Aug 24, 2026, 7:30 PM EDT

Cyclerion Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1.92.072-0.33.94
Revenue Growth
-12.60%3.70%---92.47%71.69%
Cost of Revenue
1.60.960.291.325.5837.64
Gross Profit
0.31.121.71-1.32-5.28-33.69
Selling, General & Admin
7.136.095.348.3313.2620.62
Operating Expenses
7.136.095.348.3313.2620.62
Operating Income
-6.82-4.97-3.63-9.65-18.54-54.31
Interest Expense
------0.02
Interest & Investment Income
0.120.130.210.360.29-
Other Non Operating Income (Expenses)
--0.36---
EBT Excluding Unusual Items
-6.71-4.85-3.06-9.29-18.25-54.33
Asset Writedown
----3.3--
Other Unusual Items
-----2.68
Pretax Income
-6.71-3.53-3.06-12.59-18.25-51.65
Earnings From Continuing Operations
-6.71-3.53-3.06-12.59-18.25-51.65
Earnings From Discontinued Operations
---7.33-25.83-
Net Income
-6.71-3.53-3.06-5.26-44.08-51.65
Net Income to Common
-6.71-3.53-3.06-5.26-44.08-51.65
Net Income Growth
------
Shares Outstanding (Basic)
433222
Shares Outstanding (Diluted)
433222
Shares Change
44.12%26.33%7.70%7.59%11.03%28.75%
EPS (Basic)
-1.73-1.11-1.21-2.25-20.28-26.39
EPS (Diluted)
-1.73-1.11-1.21-2.25-20.28-26.39
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-4.52-3.31-4.33-21.25-40.61-36.52
Free Cash Flow Per Share
-1.17-1.04-1.72-9.09-18.69-18.66
Gross Margin
15.95%53.76%85.70%---
Operating Margin
-359.16%-239.78%-181.40%--6242.42%-1377.83%
Profit Margin
-353.00%-170.11%-152.85%--14841.08%-1310.17%
Free Cash Flow Margin
-237.74%-159.79%-216.65%--13673.74%-926.53%
EBITDA
----9.58-18.48-53.84
D&A For EBITDA
---0.070.070.47
EBIT
-6.82-4.97-3.63-9.65-18.54-54.31
EBIT Margin
--239.78%-181.40%---
Revenue as Reported
1.92.072-0.33.94
SEC Filings: 10-K · 10-Q